iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Zydus Lifesciences bags USFDA approval for Estradiol Transdermal System

2 Dec 2022 , 02:08 PM

USFDA

United States Food and Drug Administration (USFDA) has given Zydus Lifesciences Limited (formerly Cadila Healthcare Limited) final approval to market Estradiol Transdermal System USP, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day.

The Estradiol Transdermal System is used to treat moderate to severe menopausal symptoms such as feelings of warmth in the face, neck, and chest, as well as sudden strong feelings of heat, hot flushes, and vaginal dryness in women. The drug will be manufactured in Moraiya, Ahmedabad, India, at the group’s formulation manufacturing facility.

Since the beginning of the filing process in FY 2003-04, the group has so far received 336 approvals and has filed over 431 ANDAs.

At around 2.12 PM, Zydus Lifesciences was trading at Rs413.80 up by 0.61% from its previous closing of Rs411.30 on the BSE. The scrip touched intraday high and low of Rs413.95 and Rs408.80 respectively.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Cadila Healthcare News
  • Cadila Healthcare Share
  • Cadila Healthcare Stock
  • Cadila Healthcare Updates
  • Estradiol Transdermal System
  • USFDA approval
  • Zydus Lifesciences Approval
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.